Diagnosis of noninfectious intermediate, posterior or panuveitis of at least 3 months duration

Treatment with greater than or equal to 20 mg/day of Prednisone at baseline or immunosuppressive drug score of greater than or equal to 5 at baseline

BCVA by ETDRS protocol better than or equal to 20/200

Intraocular pressure of 24 mmHg or less

Anterior chamber cells and vitreous haze of less than or equal to 1

Male or females, aged 12 or greater, body weight of 40 kg or greater

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis